A carregar...
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal
Only 1%–5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)—the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, b...
Na minha lista:
| Publicado no: | Neurol Clin Pract |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Academy of Neurology
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798502/ https://ncbi.nlm.nih.gov/pubmed/29473642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f0a9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|